<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838704</url>
  </required_header>
  <id_info>
    <org_study_id>RCMvsCM</org_study_id>
    <nct_id>NCT04838704</nct_id>
  </id_info>
  <brief_title>Ruxolitinib With Calcineurin and Methotrexate vs. Calcineurin Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Ruxolitinib With Calcineurin and Methotrexate vs. Calcineurin Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low Dose Ruxolitinib with Calcineurin and Methotrexate vs. Calcineurin plus Methotrexate and&#xD;
      Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical&#xD;
      hematopoietic stem cell transplantation in low-dose antithymocyte globulin (ATG) system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The is a prospective, randomized two-arm, and multicenter study. To compare the efficacy and&#xD;
      safety of low-dose ruxolitinib combined with calcineurin and methotrexate vs. calcineurin&#xD;
      plus methotrexate and mycophenolate mofetil as graft versus host disease prophylaxis for&#xD;
      HLA-haploidentical hematopoietic stem cell transplantation in low-dose antithymocyte globulin&#xD;
      (ATG) system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>100-day cumulative II-IV aGVHD incidence after HSCT</measure>
    <time_frame>100-day after HSCT through study completion, an average of 1 year</time_frame>
    <description>100-day cumulative II-IV aGVHD incidence after HSCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cumulative cGVHD incidence</measure>
    <time_frame>Time after HSCT through study completion, an average of 1 year</time_frame>
    <description>cGVHD incidence after HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Time after HSCT through study completion, an average of 1 year</time_frame>
    <description>overall survival after HSCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>Time after intervention through study completion, an average of 1 year</time_frame>
    <description>drug related adverse effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of relapse after HSCT</measure>
    <time_frame>Time after HSCT through study completion, an average of 1 year</time_frame>
    <description>cumulative incidence of relapse after HSCT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>RUX group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib+Calcineurin +Methotrexate</intervention_name>
    <description>low-dose ruxolitinib combine with calcineurin and short course of methotrexate.</description>
    <arm_group_label>RUX group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin +Methotrexate+Mycophenolate mofetil</intervention_name>
    <description>calcineurin and short course of methotrexate and mycophenolate mofetil</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be diagnosed with malignant hematological disease.&#xD;
&#xD;
          2. aged 12-70 years.&#xD;
&#xD;
          3. Received HLA-haploidentical hematopoietic stem cell transplantation.&#xD;
&#xD;
          4. received myeloablative conditioning&#xD;
&#xD;
          5. Karnofsky score ≥70.&#xD;
&#xD;
          6. creatinine clearance ≥60 mL/min (according to the Cockcroft-Gault formula). (7) liver&#xD;
             and kidney function: aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 ×&#xD;
             upper limit of the normal range (ULN), total bilirubin ≤ 2 × ULN; serum creatinine ≤&#xD;
             1.5 × ULN.&#xD;
&#xD;
        8) left ventricular ejection fraction (LVEF) ≥ 50% on echocardiography (ECHO). 9) life&#xD;
        expectancy &gt;12 weeks. 10) Voluntarily signed the consent form and could understand and&#xD;
        comply with the requirements of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active autoimmune disease, such as SLE, rheumatoid arthritis, etc.&#xD;
&#xD;
          2. Current clinically significant active cardiovascular disease such as uncontrolled&#xD;
             arrhythmia, uncontrolled hypertension, congestive heart failure, any grade 3 or 4&#xD;
             heart disease as determined by New York Heart Association (NYHA) functional class, or&#xD;
             a history of myocardial infarction within 6 months prior to enrollment.&#xD;
&#xD;
          3. Other serious medical conditions that may limit the patient's participation in this&#xD;
             trial (e.g., progressive infection, uncontrolled diabetes).&#xD;
&#xD;
          4. human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          5. cirrhosis of the liver, active hepatitis.&#xD;
&#xD;
          6. Pregnant or lactating women.&#xD;
&#xD;
          7. Patients who are concurrently enrolled in any clinical trials of similar drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yanmin Zhao, PhD</last_name>
    <phone>+8615858199217</phone>
    <email>zjzhaoyanmin@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang Medical Colleage Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanmin Zhao, PhD</last_name>
      <phone>+8615858199217</phone>
      <email>zjzhaoyanmin@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 5, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Graft Versus Host Disease</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>HLA-haploidentical hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

